Cocrystal Pharma Inc. (NASDAQ:COCP) does about 4.91M shares in volume on a normal day but saw 2835430 shares change hands in Tuesday trading. The company now has a market cap of 51.02M USD and an enterprise value of about $35.62M. Its current market price is $1.00, marking a decrease of -5.87% compared to the previous close of $1.06. The 52 week high reached by this stock is $3.04 whilst the lowest price level in 52 weeks is $0.39. The script in recent trading has seen the stock touch a high of $1.06 and a low of $0.9502.

Cocrystal Pharma Inc. (COCP) has a 20-day trading average at $1.6959 and the current price is -67.18% off the 52-week high compared with 158.43% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.7459 and its 200-day simple moving average is $1.0299. If we look at the stock’s price movements over the week, volatility stands at 7.66%, which increases to 11.96% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 27.42 to suggest the stock is oversold.

2 analysts observing the Cocrystal Pharma Inc. (COCP) stock have set the 12-month price targets for the company’s shares at between $5.00 and $5.00. The median price target is 80.0% away from the current levels at $5.00.

FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 08, 2020 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $5.

The current price level is -43.36%, -43.06%, and -2.87% away from its SMA20, SMA50, and SMA200 respectively, with the COCP price moving above the 50-day SMA on September 01. Cocrystal Pharma Inc. (COCP) stock is down -30.22% over the week and -57.72% over the past month. Its price is 101.37% year-to-date and -55.66% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.07 below consensus estimates by -$0.03. The company’s next earnings report is expected on 11/17/2020, with forecasts estimating quarterly EPS at -$0.05 and -$0.18 for whole year. Expected sales for next quarter are $450k, which analysts say will come at $1.85 million for the current fiscal year and next year at $1.95 million. In addition, estimates put the company’s current quarterly revenue at an average of $450k.

Its 12-month price target is $5.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $5.00.

Outstanding shares total 52.14M with insiders holding 38.38% of the shares and institutional holders owning 16.73% of the company’s common stock. The company has a return on investment of -187.60% and return on equity of -126.70%. The beta has a value of -0.20. Price to book ratio is 1.41 and price to sales ratio is 26.85.

According to a U.S. Securities and Exchange Commission filing, LSP Life Sciences Fund NV has added its position in Cocrystal Pharma Inc. (COCP) to 1,356,196 shares, mirroring a recent increase by 1.10%. LSP Life Sciences Fund NV added 14706.0 shares of Cocrystal Pharma Inc. common stock bringing its total worth to about $2.29 million at the end of recent close, SEC documents show. LSP Life Sciences Fund NV isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which added 0.21 million shares to end up with 543,630 shares worth $0.92 million. Vanguard Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.94% position in Cocrystal Pharma Inc. thanks to 0.49 million shares amounting to $0.83 million.